arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

NeuroPace Inc

NPCE
$14.79 ▲ +0.88 (+6.33%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
26 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

NeuroPace Inc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $498.7M
Dividend Yield
Revenue Growth -2.0%
Op. Margin -25.2%
ROIC -6.0%
FCF / Share $-0.18
Trailing P/E
Price / Book 34.7x
FCF Yield
Debt / Equity 4.08
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.07M
↓ -2.0%
Net Income Profit after all expenses
$-6.69M
↓ -1.5%
Operating Margin Operating profit as % of sales
-25.2%
↓ -279.7% 11th
FCF / Share Free cash flow per share
$-0.18
↑ +25.3%
Long-Term Debt Long-term obligations
$59.02M
— +0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
7
Financial Health
24
Cash Quality
41

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters